Clinical Trial Update: Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial update exploring whether hematopoietic stem cell factors influence residual inflammatory cardiovascular risk in individuals with Type 2 Diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Type 2 Diabetes | Phase 4 | Status: UNKNOWN